These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 9164776)

  • 1. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods.
    Gregg RG; Simantel A; Farrell PM; Koscik R; Kosorok MR; Laxova A; Laessig R; Hoffman G; Hassemer D; Mischler EH; Splaingard M
    Pediatrics; 1997 Jun; 99(6):819-24. PubMed ID: 9164776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols.
    Gregg RG; Wilfond BS; Farrell PM; Laxova A; Hassemer D; Mischler EH
    Am J Hum Genet; 1993 Mar; 52(3):616-26. PubMed ID: 7680526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thirty-years of screening for cystic fibrosis in East Anglia.
    Calvin J; Hogg SL; McShane D; McAuley SA; Iles R; Ross-Russell R; MacLean FM; Heeley ME; Heeley AF;
    Arch Dis Child; 2012 Dec; 97(12):1043-7. PubMed ID: 23076339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels.
    Massie RJ; Wilcken B; Van Asperen P; Dorney S; Gruca M; Wiley V; Gaskin K
    J Pediatr; 2000 Aug; 137(2):214-20. PubMed ID: 10931414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
    J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test.
    Rock MJ; Mischler EH; Farrell PM; Bruns WT; Hassemer DJ; Laessig RH
    Pediatr Pulmonol; 1989; 6(1):42-8. PubMed ID: 2704582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening.
    Keiles S; Koepke R; Parad R; Kharrazi M;
    J Cyst Fibros; 2012 May; 11(3):257-60. PubMed ID: 22209734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
    Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
    Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from 20 years of newborn screening for cystic fibrosis.
    Massie RJ; Curnow L; Glazner J; Armstrong DS; Francis I
    Med J Aust; 2012 Jan; 196(1):67-70. PubMed ID: 22256939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
    Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
    Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
    Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
    Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
    Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
    Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey of newborn screening for cystic fibrosis in Europe.
    Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
    J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
    Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
    Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
    Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
    Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.